NUZ Neurizon Therapeutics Limited
Healthcare · Biotechnology
· website
$0.06
52wk 0.06 – 0.17
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$48.44M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.03
Dividend yield
—
Payout ratio
0.0%
Beta
1.32
EV / EBITDA
-1.81
Price / Book
4.17
ROE
-147.1%
Operating margin
-91.0%
Net margin
-248.4%
Total cash
$7.95M
Total debt
$1.62M
Current ratio
2.18
Debt / Equity
0.20
Free cash flow
$-8.85M
Avg volume
896,245
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$18.48M
- Net income-$16.59M
- Diluted EPS-0.03
- Free cash flow-$14.29M
- Net debt-$4.16M